ArticleJournal of virology2018
Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans.
Article in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 42 citations in OpenAlex.
- Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of age: a randomised, active-controlled, non-inferiority trial.Nature communications · 2025Trial
- Predictors of 5-Year Persistence of Antibody Responses to Zoster Vaccines.The Journal of infectious diseases · 2023Trial
- Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines.Journal of virology · 2021Trial
- Varicella zoster virus and the central nervous system.Nature reviews. Microbiology · 2026Review
- Progress and prospects for herpesvirus vaccination using gB antigens.Frontiers in immunology · 2026Review
- Discovery and structural investigation of Varicella-Zoster virus gE-neutralizing antibodies isolated from a convalescent patient.Protein & cell · 2025Article
- Identification of linear B-cell epitopes on the gE envelope protein of varicella-zoster virus.Microbiology spectrum · 2025Article
- Characterization of neutralizing versus binding antibody and T cell responses to varicella-zoster virus in the elderly.Scientific reports · 2025Article
- The Reduced Immunogenicity of Zoster Vaccines in CMV-Seropositive Older Adults Correlates with T Cell Imprinting.Vaccines · 2025Article
- A highly stable lyophilized mRNA vaccine for Herpes Zoster provides potent cellular and humoral responses.NPJ vaccines · 2025Article
- Structures of the Varicella Zoster Virus Glycoprotein E and Epitope Mapping of Vaccine-Elicited Antibodies.Vaccines · 2024Article
- A pre-vaccination immune metabolic interplay determines the protective antibody response to a dengue virus vaccine.Cell reports · 2024Article
- Immunogenicity of Recombinant Zoster Vaccine: A Systematic Review, Meta-Analysis, and Meta-Regression.Vaccines · 2024Review
- Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine.NPJ vaccines · 2024Article
- Cross-reactive humoral immunity of clade 2 Oka and MAV/06 strain-based varicella vaccines against different clades of varicella-zoster virus.Human vaccines & immunotherapeutics · 2023Article
- Review
- Selective retention of virus-specific tissue-resident T cells in healed skin after recovery from herpes zoster.Nature communications · 2022Article
- The Immune Signatures data resource, a compendium of systems vaccinology datasets.Scientific data · 2022Article
- The next frontier in vaccine design: blending immune correlates of protection into rational vaccine design.Current opinion in immunology · 2022Review
- Geriatric Nutritional Risk Index assessment in elderly patients during the COVID-19 outbreak.Health science reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
Abstract
Herpes zoster (HZ) (shingles) is the clinical manifestation of varicella-zoster virus (VZV) reactivation. HZ typically develops as people age, due to decreased cell-mediated immunity. However, the importance of antibodies for immunity against HZ prevention remains to be understood. The goal of this study was to examine the breadth and functionality of VZV-specific antibodies after vaccination with a live attenuated HZ vaccine (Zostavax). Direct enumeration of VZV-specific antibody-secreting cells (ASCs) via enzyme-linked immunosorbent spot assay (ELISPOT assay) showed that Zostavax can induce both IgG and IgA ASCs 7 days after vaccination but not IgM ASCs. The VZV-specific ASCs range from 33 to 55% of the total IgG ASCs. Twenty-five human VZV-specific monoclonal antibodies (MAbs) were cloned and characterized from single-cell-sorted ASCs of five subjects (>60 years old) who received Zostavax. These MAbs had an average of ∼20 somatic hypermutations per VH gene, similar to those seen after seasonal influenza vaccination. Fifteen of the 25 MAbs were gE specific, whereas the remaining MAbs were gB, gH, or gI specific. The most potent neutralizing antibodies were gH specific and were also able to inhibit cell-to-cell spread of the virus
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.